[1]邓哲 梁凤楚 吴爵非.性别在射血分数的心力衰竭中的差异相关机制[J].心血管病学进展,2021,(10):897.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.008]
　DENG ZheLIANG Fengchu,WU Juefei?/html>.Gender Difference in Heart Failure with Normal Ejection Fraction?nd Related Mechanisms[J].Advances in Cardiovascular Diseases,2021,(10):897.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.008]
点击复制

性别在射血分数的心力衰竭中的差异相关机制()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年10期
页码:
897
栏目:
综述
出版日期:
2021-10-25

文章信息/Info

Title:
Gender Difference in Heart Failure with Normal Ejection Fraction?nd Related Mechanisms
作者:
邓哲 梁凤楚 吴爵非
(南方医科大学附属南方医院心血管内科,广州 510515)
Author(s):
DENG ZheLIANG Fengchu;  WU Juefei?/html>
(Department of CardiologyNanfang Hospital,Southern Medical University,Guangzhou 510515,Guangdong,China)
关键词:
心血管疾病; 射血分数的心力衰竭; 性别; 预后; 沙库巴曲缬沙坦钠
Keywords:
Cardiovascular disease; Heart failure with preserved ejection fraction;  Gender;  Prognosis;  Sacubitril/Valsartan
DOI:
10.16806/j.cnki.issn.1004-3934.2021.10.008
摘要:
射血分数的心力衰竭是一个日益增的公共卫生问题，已成为心力衰竭的主要类。流行病学数据表明，女性的比例于男性，并且在预后方面，男女性也存在很大的差异，有证据表明女性患者的心血管事件死亡风险和住院率更。女性常常生活质量较差，所引起功能障碍更严重。拟通过分析男女性在病理生理上的差异、危因素的不同以预后的异同，为实践最佳个体化治疗、改善患者的预后提供基础。
Abstract:
Heart failure with normal ejection fraction (HFnEF) is a growing public health issue,and has become the primary type of heart failure(HF). Epidemiological data indicate that the prevalence of HFnEF is higher in women than in men, and there are significant differences in prognosis between men and women. There are evidences that compared to men,women with HFnEF have a lower risk of cardiovascular death and lower rates of hospitalization, yet would typically have worse quality of life and more severe dysfunction associated with HF. This paper attempts to analyze the pathophysiological differences, the differences in risk factors,and the similarities and differences in prognosis between men and women with HFnEF, so as to provide the basis for practicing optimal individualized treatment and improving the prognosis of patients with HFnEF.

参考文献/References:

[1] Borlaug BAPaulus WJ. Heart failure with preserved ejection fraction:pathophysiology,diagnosis,and treatment[J]. Eur Heart J,2011,32(6):670-679.
[2] Lekavich CL,Barksdale DJ,Neelon V,et al. Heart failure preserved ejection fraction (HFpEF):an integrated and strategic review[J].?Heart Fail Rev,2015;20(6):643-653.
[3] Ho JE,Gona P,Pencina MJ,et al. Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community[J]. Eur Heart J,2012,33(14):1734-1741.
[4] Masoudi F A,Havranek E P,Smith G,et al. Gender,age,and heart failure with preserved left ventricular systolic function[J]. J Am Coll Cardiol,2003,41(2):217-223.
[5] Beale AL,Nanayakkara S,Kaye DM. Impact of sex on ventricular-vascular stiffness and long-term outcomes in heart failure with preserved ejection fraction:TOPCAT trial substudy[J]. J Am Heart Assoc,2019,8(13):e012190.
[6] Crea F,Bairey MC,Beltrame JF,et al. The parallel tales of microvascular angina and heart failure with preserved ejection fraction:a paradigm shift[J]. Eur Heart J,2017,38(7):473-477.
[7] Naoki F,Barry AB,Gregory DL,et al. Hemodynamic responses to rapid saline loading:the impact of age,sex,and heart failure[J]. Circulation,2013,127(1):55-62.
[8] McHugh K,DeVore AD,Wu J,et al. Heart failure with preserved ejection?fraction and diabetes:JACC state-of-the-art review[J].?J Am Coll Cardiol,2019,73(5):602-611.
[9] Kannel WB,Hjortland M,Castelli WP. Role of diabetes in congestive heart failure:the Framingham study[J]. Am J Cardiol,1974,34(1):29-34.
[10] Messerli FH,Rimoldi SF,Bangalore S. The transition from hypertension to?heart?failure:contemporary update[J]. JACC Heart Fail,2017,5(8):543-551.?
[11] Martens P,Nijst P,Verbrugge FH,et al. Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced,mid-range and preserved ejection fraction[J].?Acta Cardiol,2018,73(2):115-123.
[12] Ewa A J,Piotr R,Agnieszka W,et al. Iron deficiency:an ominous sign in patients with systolic chronic heart failure[J]. Eur Heart J,2010,31(15):1872-1880.
[13] Jaarsma T, van der Wal MH, Lesman-Leegte I, et al. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH).?Arch Intern Med. 2008;168(3):316-324.
[14] Abernethy A,Raza S,Sun J L,et al. Pro-inflammatory biomarkers in stable versus acutely decompensated heart failure with preserved ejection fraction[J]. J Am Heart Assoc,2018,7(8):e007385.
[15] Sabra LK,Katie LF. Sex differences in immune responses[J]. Nat Rev Immunol,2016,16(10):626-638.
[16] Zhao D,Guallar E,Ouyang P,et al. Endogenous sex hormones and incident?cardiovascular disease in post-menopausal women[J]. J Am Coll Cardiol,2018,71(22):2555-2566.
[17] Subramanya V,Zhao D,Ouyang P,et al. Sex hormone levels and change in left ventricular structure among men and post-menopausal women:The Multi-Ethnic Study of Atherosclerosis (MESA)[J]. Maturitas,2018,108:37-44.
[18] Keskin M,Av?ar ?,Hay?ro?lu M?,et al. Relation of the number of parity to left ventricular diastolic function in pregnancy[J].?Am J Cardiol,2017,120(1):154-159.
[19] Wu P,Haththotuwa R,Kwok CS,et al. Preeclampsia and future cardiovascular health:a systematic review and meta-analysis[J].?Circ Cardiovasc Qual Outcomes,2017,10(2):e003497.
[20] Melchiorre K,Sharma R,Thilaganathan B. Cardiovascular implications in preeclampsia:an overview[J].?Circulation,2014,130(8):703-714.
[21] Rosano GMC,Lewis B,Agewall S,et al. Gender differences in the effect of cardiovascular drugs:a position document of the Working Group on Pharmacology and Drug Therapy of the ESC:Figure?1[J]. Eur Heart J,2015,36(40):2677-2680.
[22] Jochmann N,Stangl K,Garbe E,et al. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases[J].?Eur Heart J,2005,26(16):1585-1595.
[23] Dewan P,R?rth R,Raparelli V,et al. Sex-related differences in heart failure with preserved ejection fraction[J]. Circ Heart Fail,2019,12(12):e006539.
[24] Solomon SD,Vaduganathan M,L Claggett B,et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure[J]. Circulation,2020,141(5):352-361.
[25] Mcmurray?JJV,Jackson AM,Lam CSP,et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction:insights from PARAGON-HF[J]. Circulation,2020,141(5):338-351.

相似文献/References:

[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
　BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(10):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
　REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(10):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
　YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(10):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
　ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(10):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
　QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(10):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
　JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(10):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
　HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(10):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
　Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(10):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
　WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(10):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]

更新日期/Last Update: 2021-12-02